1 Day
Source:
The Boston Globe
_1777370220974_847775619.png&w=48&q=75){kind=small}
Patent loophole enables access to costly drug
A family from South Africa traveled to Bangladesh to purchase a cheaper, locally produced generic version of the cystic fibrosis drug Trikafta, which is unaffordable in many countries due to high prices set by the patent-holder, Vertex Pharmaceuticals. The Bangladeshi drug, Triko, costs significantly less and has been approved by Bangladesh's regulatory authority, providing access to life-changing treatment for patients who cannot afford the original. This reverse-engineered medication offers hope to many with cystic fibrosis in developing countries, despite ongoing legal and patent disputes.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)